Zivo Bioscience Inc. (ZIVO)
Stock Price:
$0.110 USD
0.000 (0.00%)
Updated Aug 4, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
44.73M |
| Revenue (ttm) |
20,000 |
| Net Income (ttm) |
-11.00M |
| Shares Out |
406.64M |
| EPS (ttm) |
-0.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$0.110 |
| Previous Close |
$0.110 |
| Change ($) |
0.000 |
| Change (%) |
0.00% |
| Day's Open |
0.103 |
| Day's Range |
0.103 - 0.108 |
| Day's Volume |
72,540 |
| 52-Week Range |
0.050 - 0.175 |
More Stats
| Market Cap |
44.73M |
| Enterprise Value |
49.95M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
406.64M |
| Float |
238.78M |
| EPS (basic) |
-0.04 |
| EPS (diluted) |
-0.03 |
| FCF / Share |
-0.01 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
0.51 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
2,236.49 |
| PB Ratio |
n/a |
| Revenue |
20,000 |
| Operating Income |
-9.79M |
| Net Income |
-11.00M |
| Free Cash Flow |
-3.91M |
| Net Cash |
-5.22M |
| Net Cash / Share |
-0.01 |
| Gross Margin |
n/a |
| Operating Margin |
-48,953.10% |
| Profit Margin |
-54,980.70% |
| FCF Margin |
-19,570.66% |
| ROA |
-4,329.44% |
| ROE |
n/a |
| ROIC |
272.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | 0.10 | 0.08 |
| Revenue Growth | - | - | - | - | - | - | - | - | 25.59% | - |
| Gross Profit | - | - | - | - | - | - | - | - | -0.03 | 0.03 |
| Operating Income | -8.35 | -6.13 | -6.33 | -3.49 | -3.06 | -5.15 | -3.11 | -2.08 | -1.94 | -4.06 |
| Net Income | -11.51 | -14.64 | -10.04 | -6.06 | -5.79 | 0.68 | -10.10 | -3.25 | -2.73 | -7.12 |
| Shares Outstanding | 276 | 157 | 139 | 134 | 131 | 125 | 112 | 101 | 96.58 | 87.16 |
| Earnings Per Share | -0.04 | -0.09 | -0.07 | -0.05 | -0.04 | - | -0.09 | -0.03 | -0.03 | -0.08 |
| Operating Cash Flow | -3.71 | -5.01 | -4.24 | -2.54 | -2.30 | -2.74 | -2.99 | -1.77 | -1.29 | -1.44 |
| Capital Expenditures | - | - | - | - | - | - | - | - | - | -0.03 |
| Free Cash Flow | -3.71 | -5.01 | -4.24 | -2.54 | -2.30 | -2.74 | -2.99 | -1.78 | -1.30 | -1.47 |
| Cash & Equivalents | 0.35 | 0.39 | 0.32 | 0.51 | 0.02 | 0.00 | 0.49 | 0.17 | 0.35 | 0.14 |
| Total Debt | 5.28 | 18.15 | 13.96 | 10.31 | 6.16 | 4.01 | 2.51 | 1.34 | 0.52 | 0.28 |
| Net Cash / Debt | -4.93 | -17.77 | -13.64 | -9.80 | -6.14 | -4.01 | -2.02 | -1.16 | -0.17 | -0.14 |
| Assets | 0.37 | 0.41 | 0.33 | 0.74 | 0.07 | 0.10 | 2.17 | 0.23 | 0.46 | 0.34 |
| Liabilities | 8.71 | 22.69 | 16.64 | 14.36 | 9.57 | 6.47 | 11.77 | 4.19 | 2.49 | 1.29 |
| Book Value | -8.34 | -22.28 | -16.30 | -13.62 | -9.50 | -6.37 | -9.59 | -3.96 | -2.03 | -0.95 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Zivo Bioscience Inc. |
| Country |
United States |
| Employees |
5 |
| CEO |
Andrew A. Dahl |
Stock Information
| Ticker Symbol |
ZIVO |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: ZIVO |
Description
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and marketing natural bioactive ingredients derived from its proprietary algal cultures. The company provides its natural bioactive ingredients to animal, human and dietary supplement, and medical food manufacturers; and intends to license its bioactive molecules as lead compounds or templates for synthetic variants intended for therapeutic applications. It is also involved in developing, manufacturing, marketing, and selling tests that would allow people to optimize their health and identify future health risks, as well as provides insurers, employers, and healthcare providers with timely information to intervene with wellness programs, fitness regimes, or other preventative measures. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Keego Harbor, Michigan.